ISAAC COHEN, OMD, PhD
President and Chief Executive Officer

Isaac Cohen, OMD, PhD, serves as the President and CEO of Iaterion. Dr. Cohen has substantial experience in all phases of drug development and biopharmaceutical company management, from start-up to NASDAQ listing. He has strong relationships with investors and Bio-Pharmaceuticals industry leadership. He brings breadth and wealth of knowledge from his 20 years of experience in R&D, regulatory, as well as the pharmaceutical business. 

Dr. Cohen was the Founder, Chairman and CEO of Bionovo, Inc. and brought the company to a NASDAQ Capital Markets listing. At Bionovo he created a preclinical research program, managed all aspects of R&D, designed and built pre-launch manufacturing plant under FDA approved cGMP and ushered drugs from bench to Phase 3 development. Isaac holds multiple patents for new drugs. Iaterion’s current focus is derived from Dr. Cohen’s targeted screening approach for discovering drugs to treat and prevent diseases.

Prior to Bionovo, Dr. Cohen was a guest scientist at UCSF Center for Reproductive Sciences and the Comprehensive Cancer Center. He was in private clinical practice for 20 years in Berkeley, CA. Dr. Cohen earned his PhD at the University of California, San Francisco and University of California, Berkeley joint program, and holds an OMD degree from the Postgraduate Institute of Traditional Chinese Medicine, Hong Kong, China.

DALE LEITMAN, MD, PhD
Chief Scientific Officer

Dale Leitman is the Chief Scientific Officer at Iaterion Inc. He is also an Adjunct Professor in the Department of Nutritional Sciences at the University of California, Berkeley. His research is focused on the mechanisms of action of nuclear receptors with a focus on estrogen receptors. Dr. Leitman’s discoveries related to selective functions of nuclear receptors and discoveries of novel ligand-drugs led to the development of new drugs for women’s diseases and novel anti-inflammatory agents. Dale has long biotechnology industry experience. As a Scientific Advisory Board member at Bionovo Dale led the drug discovery program for Women’s Health.

Dale earned his B.S. degree at UC Berkeley. He received his PhD in Physiology at Stanford University. Ferid Murad, Nobel Laureate was his advisor. He completed a postdoctoral fellowship in Endocrinology at UCSF with John Baxter, President Emeritus, Endocrine Society. He obtained a MD at UC Davis School of Medicine and completed residency in Obstetrics, Gynecology and Reproductive Sciences at UCSF. He was on faculty in Obstetrics, Gynecology and Reproductive Sciences at UCSF for 12 years before joining the faculty at UC Berkeley. 

MARIELLE COHEN, MSc
Interim Chief Business Officer

Marielle Cohen, M.Sc. serves as Iaterion's Interim Chief Business Officer. Marielle has significant experience in market research and business development. She understands the biopharmaceutical competitive landscape and Iaterion's competitive advantage, pricing and bio-valuation analysis, as well as insurance coverage and compensation. Ms. Cohen develops all marketing materials and investor presentations for Iaterion’s products and platforms. She also spearheads business development efforts for Iaterion products and licensing agreements with potential partners.

Marielle worked on marketing, sales and strategy development for IBM Inc. At IBM, Inc. Marielle worked on product strategy and AI implementation with major medical device companies. She recently joined Deliotte Consulting as a strategy consultant within their Sales and Service Excellence division.

Marielle graduated from Vanderbilt University with a major in biology and neuroscience and a minor in psychology. She received her M.Sc. in commerce from the University of Virginia, McIntire School of Commerce.

KLAUS D. KOHL, PhD
Chief Technical Officer

Dr. Kohl is an experienced biopharmaceutical executive. He brings 30 years of experience in developing and managing all aspects of drug development, manufacturing and regulatory controls. Klaus’ focus is on CMC, Quality (Assurance and Control), Development and Manufacturing Strategies, Regulatory Strategies from IND to NDA filings, establishments of commercial supply chains, product launch readiness and program management for pharmaceutical companies including small molecules, Biosimilars, botanical - and combination drug-device products.

Dr. Kohl has experience in "big" Pharma companies (Bayer, Novo Nordisk (inhalable Insulin), Genentech/Roche (establishment of a world-wide CMO Business) and Merck (MSD) as well as smaller start-up companies like ARADIGM and NEKTAR in the US, Asia and Europe. Dr. Kohl is a very successful manager, running organizations from 10 up to 1500 people, in positions from VP, SVP and C level Officer.

Klaus, received his PhD at the Institute of Neurobiology Research Center, Juelich, Germany, where he developed his very solid research capabilities (Research of visual transduction). Following his PhD work, Dr. Kohl joined the Max Planck Society, Germany (one of the best research organizations in Germany) where he continued his research work on membrane proteins, reporting directly to the President of the Max Planck Society. Klaus was rewarded the Humboldt scholarship to continue the research work at the UCSF. In the mid 80’s, Dr. Kohl joined the Pharmaceutical Industry with Bayer. 

Lorin Johnson, PhD
Scientific Advisor

Lorin K. Johnson, PhD is founder and Chief Scientist of Glycyx PharmaVentures Ltd., a biopharma investment and development company. In 1989, he co-founded Salix Pharmaceuticals, Inc. (Nasdaq: SLXP), a GI specialty pharmaceutical company, and held senior leadership positions prior to its $15.8 billion acquisition by Bausch Health Inc. (NYSE: BHC) in April 2015. Prior to Salix, Dr. Johnson served as Director of Scientific Operations and Chief Scientist at Scios, Inc. (formerly California Biotechnology, Inc). He is a board member of 9Meters Biopharma Inc. (Nasdaq: NMTR) and Edesa Biotech. Inc. (Nasdaq: EDSA), Glycyx MOR, Inc. and Kinisi Therapeutics, Ltd., both GI specialty pharma companies and Intact Therapeutics, Inc., a GI specialty drug delivery company. In addition to his career in industry, Dr. Johnson has served as Assistant Professor of Pathology at Stanford University School of Medicine. He is the co-author of 75 journal articles and book chapters and is the coinventor on 22 issued patents. Dr. Johnson holds a Ph.D. from the University of Southern California and was a Postdoctoral Fellow at the University of California, San Francisco.

CARLOS E. MILLA, MD
Scientific Advisor

Carlos Milla is Professor of Pediatrics at Stanford University School of Medicine, where he is also Associate Director for Translational Research at the Center for Excellence in Pulmonary Biology at Stanford. Dr Milla graduated from Medical School in Lima Peru, completed Residency in Pediatrics at the Children’s Medical Center of Brooklyn, State University of New York, and then went on to complete sub-specialty training in Pediatric Pulmonology and Cystic Fibrosis at the University of Minnesota, as well as advanced training in Epidemiology and Biostatistics. In 2007 Dr Milla joined the faculty at the Center for Excellence in Pulmonary Biology at Stanford University and became the Director of the Stanford Cystic Fibrosis Center. He has been a member of the ATS since 1992 and a member of the Pediatric Assembly since 1993.  He is a member of the ATS/ERS Joint Working Group on Infant/Preschool Lung Function, and has also served on the ATS project committees for Standardization of Preschool Inert Gas Washout and Diagnosis of primary ciliary dyskinesia.

Dr Milla’s research interests have centered on the inflammatory responses that lead to airway disease in Cystic Fibrosis and the pathobiology of infections in the airway. He has actively participated in multiple CF clinical research studies and has accumulated substantial experience on the development of novel outcomes in CF. This includes participation in multiple clinical trials, from early phase to pivotal trials, as well as participating in multiple advisory boards for drug development focused on CF.  Dr Milla has published and lectured extensively on the topics of cystic fibrosis and the genetics of rare lung diseases. Current areas of research include early CF lung disease development and diagnostic challenges in newborns identified by screening, as well as expanding his research interests with active programs for biomarker discovery for chronic pulmonary conditions such as primary ciliary dyskinesia, pulmonary hypertension, chronic lung disease of infancy and interstitial lung disease.

UWE CHRISTIANS, MD, PhD
Scientific Advisor

Professor of Anesthesiology and Pathology, iC42 Clinical Research and Development, University of Colorado, Anschutz Medical Campus, Denver, Colorado, USA

Dr. Christians received his M.D. (with highest honors) and his Ph.D. in Experimental and Clinical Pharmacology and Toxicology from the Medizinische Hochschule Hannover, Hannover, Germany, where he is a board-certified pharmacologist, toxicologist and clinical pharmacologist. He is also a Diplomate of the American Board of Clinical Pharmacology. Dr. Christians currently holds two faculty appointments, one as Professor in the Department of Anesthesiology (University of Colorado) and as Professor (apl.) in the Department of Pharmacology, Medizinische Hochschule Hannover in Germany. He is the author of more than 300 peer-reviewed original research articles, reviews and book chapters as well as the Editor-in-Chief of the IATDMCT journal Therapeutic Drug Monitoring. In 1995, he received the IATDMCT Young Investigator Award and, in 2015, the IADTMCT C.E. Pippenger Award. His main research interest is pharmacokinetics/ pharmacodynamics relationships, companion biomarkers in drug development and “precision drug therapy”, including, but not limited to, the development of novel translational, diagnostic and clinical monitoring strategies.

JEN-CHYWAN (WALLY) WANG, PhD
Scientific Advisor

Dr. Jen-Chywan Wang received his PhD at Vanderbilt University, where he studied how steroid hormone glucocorticoids activate the transcription of phosphoenolpyruvate carboxykinase gene that encodes a rate-controlling enzyme in gluconeogenesis. He then conducted his post-doctoral training at University of California San Francisco, where he explored the approach to identify glucocorticoid receptor (GR) primary target genes and the mechanisms governing the regulation of GR activity by ligands. Dr. Wang joined the Department of Nutritional Sciences & Toxicology at UC Berkeley as a tenure-track faculty on August 2006. His laboratory applies a combination of molecular and cellular biological, genomic, genetic and physiological approaches to elucidate the mechanisms underlying the physiological and pharmacological actions of GR. These topics include the identification of GR primary target genes that mediate biological functions of glucocorticoids, the exploration of the mechanisms governing the transcriptional activation of GR primary target genes, and the discovery of GR transcriptional coregulators involved in specific physiological actions of glucocorticoids.

ISAAC COHEN, OMD, PhD
Chairman of the Board of Directors

Isaac Cohen, OMD, PhD, serves as the President and CEO of Iaterion. Dr. Cohen has substantial experience in all phases of drug development and biopharmaceutical company management, from start-up to NASDAQ listing. He has strong relationships with investors and Bio-Pharmaceuticals industry leadership. He brings breadth and wealth of knowledge from his 20 years of experience in R&D, regulatory, as well as the pharmaceutical business. 

Dr. Cohen was the Founder, Chairman and CEO of Bionovo, Inc. and brought the company to a NASDAQ Capital Markets listing. At Bionovo he created a preclinical research program, managed all aspects of R&D, designed and built pre-launch manufacturing plant under FDA approved cGMP and ushered drugs from bench to Phase 3 development. Isaac holds multiple patents for new drugs. Iaterion’s current focus is derived from Dr. Cohen’s targeted screening approach for discovering drugs to treat and prevent diseases.

Prior to Bionovo, Dr. Cohen was a guest scientist at UCSF Center for Reproductive Sciences and the Comprehensive Cancer Center. He was in private clinical practice for 20 years in Berkeley, CA. Dr. Cohen earned his PhD at the University of California, San Francisco and University of California, Berkeley joint program, and holds an OMD degree from the Postgraduate Institute of Traditional Chinese Medicine, Hong Kong, China.

Lorin Johnson, PhD
Member of the Board of Directors

Lorin K. Johnson, PhD is founder and Chief Scientist of Glycyx PharmaVentures Ltd., a biopharma investment and development company. In 1989, he co-founded Salix Pharmaceuticals, Inc. (Nasdaq: SLXP), a GI specialty pharmaceutical company, and held senior leadership positions prior to its $15.8 billion acquisition by Bausch Health Inc. (NYSE: BHC) in April 2015. Prior to Salix, Dr. Johnson served as Director of Scientific Operations and Chief Scientist at Scios, Inc. (formerly California Biotechnology, Inc). He is a board member of 9Meters Biopharma Inc. (Nasdaq: NMTR) and Edesa Biotech. Inc. (Nasdaq: EDSA), Glycyx MOR, Inc. and Kinisi Therapeutics, Ltd., both GI specialty pharma companies and Intact Therapeutics, Inc., a GI specialty drug delivery company. In addition to his career in industry, Dr. Johnson has served as Assistant Professor of Pathology at Stanford University School of Medicine. He is the co-author of 75 journal articles and book chapters and is the coinventor on 22 issued patents. Dr. Johnson holds a Ph.D. from the University of Southern California and was a Postdoctoral Fellow at the University of California, San Francisco.